Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

• Status: Unknown status
• Trial end date: 2021-08-30
• Target enrollment: 0
• Participant gender: All

Summary

This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited lymph node metastasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Collaborators: Affiliated Hospital of Hebei University; Anyang Tumor Hospital; Fujian Cancer Hospital; Hebei Medical University Fourth Hospital; Sichuan Cancer Hospital and Research Institute; The First Affiliated Hospital with Nanjing Medical University; Tianjin Medical University Cancer Institute and Hospital
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Age<70

• Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002）

• A untreated squamous esophageal carcinoma

• Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3

• Adequate organ function

• No known history of drug allergy

• Blood routine examination : WBC≥4.0

• hepatic and renal function are normal

Exclusion Criteria:

• Age≥ 70 or < 18

• Already received the treatment of chemotherapy or radiotherapy

• Pregnant or lactating females

• Known drug allergy

• Without agreement of informed consent form

• Insufficient hepatorenal function or Blood routine examination

• Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.